Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health enterprise, speaks throughout an interview with CNBC throughout his firm’s IPO on the New York Inventory Alternate (NYSE), Could 4, 2023.
Brendan McDermid | Reuters
Tylenol maker Kenvue’s CEO and board member Thibaut Mongon has stepped down, it mentioned on Monday and named firm director Kirk Perry as interim chief government.
The corporate, which was spun off from Johnson & Johnson in 2023, has been beneath stress from activist traders to spice up efficiency, notably in its skin-health and wonder unit, which incorporates manufacturers resembling Neutrogena and Aveeno.
“The Board’s strategic assessment is underway, and we’re contemplating a broad vary of potential options, together with methods to simplify the corporate’s portfolio and the way it operates,” mentioned board chair Larry Merlo.
Perry has beforehand spent 23 years with Procter & Gamble. He most not too long ago served as president and CEO of Circana, a world supplier of know-how, information and predictive analytics for the buyer, retail and media sectors.